
AbbVie (ABBV) Stock Forecast & Price Target
AbbVie (ABBV) Analyst Ratings
Bulls say
AbbVie is anticipated to achieve a high single-digit sales compound annual growth rate (CAGR) from 2024 to 2029, supported by robust expectations for its key products, particularly Skyrizi and Rinvoq. The revised sales forecast for Skyrizi now exceeds $20 billion and for Rinvoq surpasses $11 billion by 2027, indicating significant market demand and product performance. Despite some softening in the Aesthetics segment outlook, AbbVie's overall strong performance in immunology and enhancements in sales estimates highlight a positive trajectory for the company's financial growth.
Bears say
AbbVie's financial outlook is challenged by several factors, including disappointing commercial execution on key products such as Skyrizi, Rinvoq, and those in the aesthetics category, which are heavily reliant on discretionary spending. Furthermore, the company faces increased competitive pressure in its oncology portfolio and significant erosion of Humira’s market share due to the introduction of biosimilars, which is expected to intensify beyond 2025. Additionally, macroeconomic headwinds, including volatility in consumer spending and regulatory challenges, further complicate AbbVie's growth prospects, particularly in the aesthetics market, where recent sales have significantly underperformed expectations.
This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.
AbbVie (ABBV) Analyst Forecast & Price Prediction
Start investing in AbbVie (ABBV)
Order type
Buy in
Order amount
Est. shares
0 shares